Scott W. Landvatter, Ph.D.

Scott W. Landvatter earned his B.S. in Chemistry from the University of Wisconsin and his Ph.D. in organic synthesis with John Katzenellenbogen at the University of Illinois. It was here that Scott first began doing organic synthesis with isotopes as he developed gamma and positron-emitting estrogens for use as breast tumor imaging agents. Scott then moved to Philadelphia and SmithKline Beckman Pharmaceuticals (soon to become SmithKline Beecham and then GlaxoSmithKline) as an isotope chemist. Scott advanced to the rank of assistant director where he was in charge of a group of chemists whose responsibility was to provide radiolabeled (14C, 3H, 125I) and stable isotope labeled (2H, 13C, 15N) compounds for drug development. After over 19 years with SmithKline, Scott moved on to found IsoSciences with David Saunders. Scott has published over 45 research articles, the majority of which describe applications of isotopes in organic synthesis including the development of new labeling methodology. He has also served as President of the International Isotope Society Northeast Section.

David Saunders, B.Sc., MRSC

David Saunders earned his B.Sc. in Applied Chemistry at the University of Hertfordshire, England. David joined the pharmaceutical industry working first with Smith & Nephew in the UK as an organic chemist before joining Beecham Pharmaceuticals and finally SmithKline & French (later to become SmithKline Beecham and GlaxoSmithKline) as an isotope chemist. David rose to become Head of Radiochemistry at SK&F, UK, and ultimately moved to the USA with SB where he assumed responsibility for directing a group of chemists in the synthesis of isotopically labeled compounds for drug development. After 33 years in the pharmaceutical industry carrying out isotopic synthesis, David left to found IsoSciences with Scott Landvatter. David is on the Advisory Board for the International Isotope Society and the Journal of Labeled Compounds and is a member of the Royal Society of Chemistry.